Better therapeutic effect was also achieved when treatment was started early (at 1 h) after the initial ischemic insult.
MI go on to develop heart failure accompanied with repeated hospitalizations, morbidity, and mortality.
Successful interventional therapies have significantly improved the outcome after an acute coronary event (6) and are now a standard of care across the globe.
However, decreased mortality after acute MI has also skewed the patient population to an increased incidence of developing heart failure within both acute and chronic settings (5) . Moreover, long-term survival in these patients with established therapies has not improved over the course of the last decade, and heart failure may even have slightly worsened according to a recent study (7) . These factors underpin the importance of discovering new therapeutic drugs that complement current post-MI pharmacological treatment with a potential to improve left ventricular (LV) dilation, ventricular remodeling, and as a result, better long-term functional outcome (8) .
Inflammation plays a central role in the evolution of pathological events after acute MI (9 ) indicate that both the direct cytotoxic aldehyde products generated by MPO-mediated reactions (15) and leukocyte recruitment and proteolysis (13) are involved in adverse outcome after acute MI and heart ischemia reperfusion injury (IRI). As such MPO has been advocated as a prognostic and risk stratification marker in cardiovascular diseases (16) .
MPO plasma levels strongly predict coronary disease prevalence (17) associated with adverse outcome (18) and need of revascularization (19) . These data also signify MPO as a potentially important therapeutic target (8) . Thus, drugs that target MPO may help ameliorate degree of inflammation, oxidative damage, and ventricular remodeling after acute MI.
In this study, we investigated a novel MPO inhibi- Figure 1A) . We then tested on mouse MPO extracted from MI and compared it with an intrinsic control without the drug. More than 80%
of MPO control activity was reduced with a dose as little as 0.61 mmol/l (Supplemental Figure 1B) .
Mouse MPO obtained from bone marrow neutrophils was also inhibited with the similar potency (Supplemental Figure 1C) . showed that the average PF-1355 exposure was maintained above 3.1 mM (Supplemental Table 1 ), which exceeds the half-maximal effective concentration level in LPS-stimulated human blood (20) .
PF-1355 INHIBITS MPO IN VIVO IN MOUSE MI AND IRI.
MPO-Gd (bis-5-hydroxytryptamide-diethylenetriaminepentaacetate-gadolinium) is an activatable magnetic resonance imaging agent for reporting extracellular MPO activity (26, 27) . It has been validated for noninvasive MPO-specific imaging in MI and was shown to be able to follow therapeutic response to atorvastatin post-MI (10). To evaluate the effects of PF-1355 in vivo, we performed MPO-Gd magnetic resonance imaging in mice on day 2 after MI ( Figure 1B ), which corresponds to the acute inflammatory phase known to have high neutrophils and inflammatory monocyte numbers (10) . As expected, the imaging metric lesion activation ratio (LAR) was elevated in the infarcted tissue. LAR reflects the amount of imaging agent activated by MPO over background, and was measured as a ratio of delayed enhancement at 60 min over nonspecific early enhancement at 15 min, as described previously (27) . In the treated group, the LAR significantly decreased (p ¼ 0.0003) ( Figure 1C ). (E) There is no significant difference in infarct area between groups at day 2 post-MI. Data plotted as mean AE SEM; *p < 0.05; **p < 0.01; ***p < 0.001.
Ali et al. On flow cytometry, significantly higher CD11b þ myeloid cell numbers were observed in the infarcted hearts on day 7 (p < 0.01) ( Figure 3C ). Interestingly, myeloid cells were still elevated on day 15 (neutrophils w4Â and Ly6C high monocytes w3.5Â elevated; p < 0.01 and p < 0.05, respectively) ( Figure 3C) compared with noninfarcted hearts. Consistent with tissue repair, higher numbers of macrophages (p < 0.01) and Ly-6C low monocytes (p < 0.05) were detected on day 15 (Supplemental Figure 3A) . These results were corroborated by detection of increased neutrophils and Ly-6C high and Ly-6C low monocytes in the blood of infarcted mice (p < 0.05, p ¼ NS, and p < 0.05, respectively) (Supplemental Figure 3B) . Ali et al.
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data that infarcted myocardium is continually exposed to MPO beyond the first week, we decided to investigate whether PF-1355 therapy should also be continued during the late remodeling phase. For this purpose, we divided infarcted mice into 2 treatment cohorts. In the first cohort, we treated mice for 7 days (early healing phase; n ¼ 8) and then stopped treatment until day 21 to see whether this short treatment trial during the proinflammatory phase would benefit remodeling ( Figures 4A and 4B) . Indeed, we found significant improvement in end-diastolic volume (EDV) compared with untreated mice with MI (p < 0.05) ( Figure 4E ). However, we did not see significant differences in ejection fraction (EF) ( Figure 4D ) and LV mass ( Figure 4F) , although a trend toward improvement was noted between the control and 7-day treatment groups.
In the second cohort, mice were treated for the entire 21 days (n ¼ 5) and compared with untreated mice with MI ( Figures 4A and 4C) . In contradistinction to the short-term treatment group, these mice not only had decreased EDV (p < 0.001) ( Figure 4E ), but also improved EF (p < 0.05) ( Figure 4D ) and LV mass compared with untreated control subjects (p < 0.001) potentially translatable clinical advantage: it may be used in conjunction with percutaneous coronary intervention and protect against reperfusion injury.
Drug efficacy can also be monitored noninvasively with MPO molecular imaging.
In addition to MI, MPO and its oxidized products play an important role in a variety of cardiovascular diseases. During the development of atherosclerosis lesions, MPO confers its deleterious effects by causing endothelial dysfunction (34) and both low-(35) and high-density lipoprotein modification (36, 37) . It also contributes to vulnerable plaque formation and rupture, and acute thrombosis (12) . Clinical studies predict that MPO is associated with both diastolic and systolic dysfunction as well as increased mortality (38, 39) . Due to these broad-spectrum detrimental effects, MPO has been increasingly considered an important therapeutic target for other cardiovascular diseases as well (40 
